<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787825</url>
  </required_header>
  <id_info>
    <org_study_id>Capso Vision SV-1</org_study_id>
    <nct_id>NCT01787825</nct_id>
  </id_info>
  <brief_title>Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease</brief_title>
  <official_title>Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capso Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capso Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical findings involving the small bowel
      obtained with the Capso Vision Video Capsule Device to those results obtained with the
      PillCam SB2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, comparative multi-center site study. The study will be
      conducted at 5 to 10 clinical sites. Up to 120 subjects will be enrolled in the study in
      order to obtain complete endoscopic results involving at least 98 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normal vs Abnormal, Overall Impression</measure>
    <time_frame>Study Completion</time_frame>
    <description>The review of images of suspected diseased small bowel to determine agreement among readers between the two image capture systems: CapsoCam SV-1 and PillCam SB2. The proportion of Normal vs Abnormal, Overall Impression based upon the result of 2 out of 3 data readers in agreement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of SB Transit Times With CapsoCam SV-1 and PillCam SB2</measure>
    <time_frame>Study Completion</time_frame>
    <description>Total transit time, was determined the time the 1st Duodenal image to the 1st cecal or IC Valve image as determined by the readers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Diagnostic Yield of CapsoCam SV-1 as Compared to PillCam SB2</measure>
    <time_frame>Study Completion</time_frame>
    <description>Comparison of Diagnostic Yield of CapsoCam SV-1 as compared to PillCam SB: Proportion of primary diagnostic yields based upon the result of 2 out of 3 readers in agreement or the consensus group result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preference Between CapsoCam SV-1 and PillCam SB2</measure>
    <time_frame>Study Completion</time_frame>
    <description>Subject preference between CapsoCam SV-1 and PillCam SB2 based on pill preference questionnaire administered to subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Intestinal Disease</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcer</condition>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>PillCam SB2 then CapsoCam SV-1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PillCam SB2 capsule then CapsoCam SV-1 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CapsoCam SV-1 then PillCam SB2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CapsoCam SV-1 capsule then PillCam SB2 capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PillCam SB2 capsule</intervention_name>
    <description>Capsule Endoscopy system</description>
    <arm_group_label>PillCam SB2 then CapsoCam SV-1</arm_group_label>
    <arm_group_label>CapsoCam SV-1 then PillCam SB2</arm_group_label>
    <other_name>capsule endoscopy system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CapsoCam SV-1</intervention_name>
    <description>Capsule endoscopy</description>
    <arm_group_label>PillCam SB2 then CapsoCam SV-1</arm_group_label>
    <arm_group_label>CapsoCam SV-1 then PillCam SB2</arm_group_label>
    <other_name>Capsule endoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 18 to 85 years of age (inclusive).

          2. Willing and able to provide written informed consent.

          3. Subjects with suspected small bowel disease who are referred for capsule endoscopy.
             Suspected small bowel disease includes suspected small bowel bleeding (including
             obscure gastrointestinal bleed), suspected or established Crohn's Disease [should have
             had patency capsule, CT or MR enterography before entry], suspected or known celiac
             disease, suspected small bowel tumor or familial polyposis syndrome.

          4. If subject was referred for capsule endoscopy (CE) for identification of occult GI
             bleeding, has the subject undergone a non-diagnostic esophagoduodenoscopy and
             colonoscopy as part of their evaluation, OR has the subject had continued bleeding
             requiring transfusion since the initial evaluation, OR does the subject have the
             following hematocrit values &lt;31% in males or &lt;28% in females.

        Exclusion Criteria:

          1. Subjects who had a prior negative capsule endoscopy (within 1 year of study).

          2. Known or suspected obstruction or stricture unless patency capsule confirms patency.

          3. Known or suspected gastrointestinal perforation.

          4. Known or suspected small bowel diverticuli.

          5. Known swallowing disorder or the inability or unwillingness to swallow pills.

          6. Radiation or chemotherapy induced enteritis.

          7. History of Zenker's or known duodenal or jejunal diverticula.

          8. Isolated diarrhea or isolated abdominal pain without alarm signs or symptoms

          9. Subjects who are high risk for undergoing surgical interventions (i.e., to
             CONFIDENTIAL CapsoVision Protocol SV-1 Revision: October 17, 2011 7 remove the capsule
             when capsule retention occurs).

         10. Subjects with DNR/DNI &quot;do not resuscitate/do not intubate&quot; status.

         11. Known or suspected gastrointestinal dysmotility.

         12. Presence of cardiac pacemaker, implanted defibrillator or other electromedical
             implant.

         13. History of skin reaction to adhesives.

         14. Subjects who in the Investigator's opinion should not consume the 2L GoLytely and 10
             mg bisacodyl study drugs, because it could pose a significant additional risk to the
             subject because of the subject's medical condition.

         15. Subjects who are scheduled for an MRI within 30 days of the last study visit.

         16. Pregnancy; females of childbearing potential must have a negative urine pregnancy test
             at screening.

         17. Prisoners.

         18. Mental and/or physical condition precluding compliance with the study and/or device
             instructions.

         19. Participation in another clinical study within past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shabana F Pasha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shabana F. Pasha, MD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts, Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziad Younes, MD</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Gastroenterology Associates GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <results_first_submitted>November 30, 2016</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intestinal disease</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>crohn disease</keyword>
  <keyword>ulcer</keyword>
  <keyword>celiac disease</keyword>
  <keyword>angioectasia</keyword>
  <keyword>polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from population of patients prescribed capsule endoscopy for OGIB</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CapsoCam SV-1 Then PillCam SB2</title>
          <description>Participants first received CapsoCam SV-1 then 30-60 minutes later received Pillcam SB2</description>
        </group>
        <group group_id="P2">
          <title>PillCam SB2 Then CapsoCam SV-1</title>
          <description>Participants first received PillCam SB2 then 30-60 minutes later receive CapsoCam SV-1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Did Not Ingest Capsules</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data Not Analyzable</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>PillCam SB2 capsule and CapsoCam SV-1 capsule in random order, PillCam SB2 capsule: Capsule Endoscopy system, CapsoCam SV-1: Capsule endoscopy
The analysis population consisted of subjects that swallowed the capsules.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Normal vs Abnormal, Overall Impression</title>
        <description>The review of images of suspected diseased small bowel to determine agreement among readers between the two image capture systems: CapsoCam SV-1 and PillCam SB2. The proportion of Normal vs Abnormal, Overall Impression based upon the result of 2 out of 3 data readers in agreement.</description>
        <time_frame>Study Completion</time_frame>
        <population>Note: Each participant swallowed both Pill Cam and CapsoCam approximately 30-60 minutes apart. the order in which the cams were swalloed was randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>CapsoCam SV-1</title>
            <description>Each participation swallowed both PillCam SB2 and CapsoCam SV-1 30-60 minutes apart. The order in which the cams were swallowed was randomized.</description>
          </group>
          <group group_id="O2">
            <title>PillCam SB2</title>
            <description>Each participation swallowed both PillCam SB2 and CapsoCam SV-1 30-60 minutes apart. The order in which the cams were swallowed was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Normal vs Abnormal, Overall Impression</title>
          <description>The review of images of suspected diseased small bowel to determine agreement among readers between the two image capture systems: CapsoCam SV-1 and PillCam SB2. The proportion of Normal vs Abnormal, Overall Impression based upon the result of 2 out of 3 data readers in agreement.</description>
          <population>Note: Each participant swallowed both Pill Cam and CapsoCam approximately 30-60 minutes apart. the order in which the cams were swalloed was randomized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>There was a comparison between normal and abnormal images. And detailed analysis of abnormal images that were considered clinical significant.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This is McNemar design.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <p_value_desc>The blinded readers assessed concordance of normal versus abnormal and overall concordance of clinically significant abnormal images.</p_value_desc>
            <method>McNemar</method>
            <param_type>percentage concordance</param_type>
            <param_value>77.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.68</ci_lower_limit>
            <ci_upper_limit>83.93</ci_upper_limit>
            <estimate_desc>Overall concordance of clinically significant abnormal images.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of SB Transit Times With CapsoCam SV-1 and PillCam SB2</title>
        <description>Total transit time, was determined the time the 1st Duodenal image to the 1st cecal or IC Valve image as determined by the readers.</description>
        <time_frame>Study Completion</time_frame>
        <population>For CapsoCam SV-1 data was captured for 112 subjects total transit time. For PillCam SB2, data was captured for 110 subjects for total transit time.</population>
        <group_list>
          <group group_id="O1">
            <title>CapsoCam SV-1</title>
            <description>Each participation swallowed both PillCam SB2 and CapsoCam SV-1 30-60 minutes apart. The order in which the cams were swallowed was randomized.</description>
          </group>
          <group group_id="O2">
            <title>PillCam SB2</title>
            <description>Each participation swallowed both PillCam SB2 and CapsoCam SV-1 30-60 minutes apart. The order in which the cams were swallowed was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of SB Transit Times With CapsoCam SV-1 and PillCam SB2</title>
          <description>Total transit time, was determined the time the 1st Duodenal image to the 1st cecal or IC Valve image as determined by the readers.</description>
          <population>For CapsoCam SV-1 data was captured for 112 subjects total transit time. For PillCam SB2, data was captured for 110 subjects for total transit time.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.85"/>
                    <measurement group_id="O2" value="3.6" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Diagnostic Yield of CapsoCam SV-1 as Compared to PillCam SB2</title>
        <description>Comparison of Diagnostic Yield of CapsoCam SV-1 as compared to PillCam SB: Proportion of primary diagnostic yields based upon the result of 2 out of 3 readers in agreement or the consensus group result.</description>
        <time_frame>Study Completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CapsoCam SV-1</title>
            <description>Each participation swallowed both PillCam SB2 and CapsoCam SV-1 30-60 minutes apart. The order in which the cams were swallowed was randomized.</description>
          </group>
          <group group_id="O2">
            <title>PillCam SB2</title>
            <description>Each participation swallowed both PillCam SB2 and CapsoCam SV-1 30-60 minutes apart. The order in which the cams were swallowed was randomized.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Diagnostic Yield of CapsoCam SV-1 as Compared to PillCam SB2</title>
          <description>Comparison of Diagnostic Yield of CapsoCam SV-1 as compared to PillCam SB: Proportion of primary diagnostic yields based upon the result of 2 out of 3 readers in agreement or the consensus group result.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mass/Polyp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulcerative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.972</p_value>
            <method>Bowkers</method>
            <param_type>percentage concordance</param_type>
            <param_value>71.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63.07</ci_lower_limit>
            <ci_upper_limit>79.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preference Between CapsoCam SV-1 and PillCam SB2</title>
        <description>Subject preference between CapsoCam SV-1 and PillCam SB2 based on pill preference questionnaire administered to subjects</description>
        <time_frame>Study Completion</time_frame>
        <population>For CapsoCam SV-1 and PillCam SB2 preference data was captured for 113 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>CapsoCam SV-1 Preference</title>
            <description>Subject preference for CapsoCam SV-1</description>
          </group>
          <group group_id="O2">
            <title>PillCam SB2</title>
            <description>Subject preference for PillCam SB2</description>
          </group>
        </group_list>
        <measure>
          <title>Preference Between CapsoCam SV-1 and PillCam SB2</title>
          <description>Subject preference between CapsoCam SV-1 and PillCam SB2 based on pill preference questionnaire administered to subjects</description>
          <population>For CapsoCam SV-1 and PillCam SB2 preference data was captured for 113 subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 30 days of Subjects' Swallowing of both cpasules: CapsoCam SV-1 and PillCam SB2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>PillCam SB Capsule and CapsoCam SV-1</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Capsule Endoscope Retention</sub_title>
                <description>Capsule Endoscopes (Both CapsoCam SV-1 and PillCam SB2) retained within the small bowel of each of two (2) enrolled subjects. Capsules were removed via surgical intervention.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Tract discomfort or pain and nausea</sub_title>
                <description>GI Tract discomfort or pain and nausea attributed to bowel preparation for the procedures by study investigators</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Malaise in one (1) subject</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Delayed Capsule Excretion</sub_title>
                <description>Delayed Capsule Excretion: Capsule s not retrieved and returned to investigator/research site for analysis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine Headache</sub_title>
                <description>Migraine Headache in one (1) subject</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Right Kidney Pain</sub_title>
                <description>Right Kidney Pain: Cause unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation and Itchiness</sub_title>
                <description>Skin Irritation and itchiness secondary to adhesive tape used to secure PillCam SB2 wireless receiver</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Affairs</name_or_title>
      <organization>CapsoVision, Inc.</organization>
      <phone>408-624-1488 ext 117</phone>
      <email>andra.thomas@capsovision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

